Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

Survival Benefit in Children with Progeria Published in JAMA 2018 NDA Filing Planned in 2019 PALO ALTO, Calif., Dec. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and ... Biopharmaceuticals, FDA Eiger BioPharmaceuticals, Lonafarnib, Progeria Syndrome, Progeroid Laminopathies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news